Catalyst Wire Dossier Catalyst Wire Dossier

PRO 140 (leronlimab)

leronlimab · CytoDyn, Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for PRO 140 (leronlimab), covering 2013-05-31 to 2026-03-04. Get the full timeline:

Most recent: Clinical Trial Update: Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection [Phase 2, Phase 3]

See pricing